Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | BLM | P54132 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA3 | P07451 | 2/20 | 0.44 |
| ▸ | CA4 | P22748 | 2/20 | 0.44 |
| ▸ | CA6 | P23280 | 2/20 | 0.44 |
| ▸ | CA5A | P35218 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.44 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL28144890 | 1.00 | FDPS (0.48) | FDPSLMNABLMCYP3A4NFKB1 | |
| Phosphoric Acid SCHEMBL27508186 | 0.97 | LMNA (0.50) | FDPSLMNABLMCYP3A4NFKB1 | |
| Phosphoric Acid SCHEMBL6535607 | 0.88 | BLM (0.52) | FDPSLMNABLMCYP3A4NFKB1 | |
| Phosphoric Acid SCHEMBL27481355 | 0.88 | BLM (0.52) | FDPSLMNABLMCYP3A4NFKB1 | |
| Phosphoric Acid SCHEMBL31656949 | 0.88 | LMNA (0.58) | FDPSLMNABLMCYP3A4NFKB1 | |
| Phosphoric Acid SCHEMBL14974535 | 0.88 | LMNA (0.58) | FDPSLMNABLMCYP3A4NFKB1 | |
| Phosphoric Acid SCHEMBL5177945 | 0.88 | LMNA (0.58) | FDPSLMNABLMCYP3A4NFKB1 | |
| Phosphoric Acid SCHEMBL5382781 | 0.88 | LMNA (0.58) | FDPSLMNABLMCYP3A4NFKB1 | |
| Diaminooctane SCHEMBL31657014 | 0.88 | LMNA (0.58) | FDPSLMNABLMCYP3A4NFKB1 | |
| SCHEMBL8949921 | 0.85 | GABBR2 (0.48) | FDPSLMNABLMCYP3A4NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485421-B2 | Polyamide-oligonucleotide derivatives, their preparation and use | HOECHST GMBH (DE) | 2009-02-03 | — | — | US | disclosed |
| CN-100379756-C | Polyamid-oligonucleotide derivative, preparation and application of same | HOECHST AG (DE) | 2008-04-09 | — | — | CN | disclosed |
| US-6919441-B2 | Polyamide-oligonucleotide derivatives, their preparation and use | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-07-19 | — | — | US | disclosed |
| US-20050026817-A1 | Polyamide-oligonucleotide derivatives, their preparation and use | AVENTIS PHARMA DEUTSCHLAND GMBH (US) | 2005-02-03 | — | — | US | disclosed |
| US-20030203359-A1 | Polyamide-oligonucleotide derivatives, their preparation and use | HOECHST MARION ROUSSEL DEUTSCHLAND GMBH | 2003-10-30 | — | — | US | disclosed |
| CN-1112126-A | Polyamid-oligonucleotide derivative, preparation and application of same | HOECHST AG (DE) | 1995-11-22 | — | — | CN | disclosed |
| EP-0224578-B2 | COMPOSITIONS AND METHODS FOR FUNCTIONALIZING NUCLEIC ACIDS | AMGEN INC (US) | 1994-11-09 | — | — | EP | disclosed |
| EP-0224578-B1 | COMPOSITIONS AND METHODS FOR FUNCTIONALIZING NUCLEIC ACIDS | AMGEN INC. (US) | 1990-08-16 | — | — | EP | disclosed |
| EP-0224577-B1 | METHOD FOR DERIVITIZATION OF POLYNUCLEOTIDES | AMGEN INC. (US) | 1990-04-25 | — | — | EP | disclosed |
| US-4762779-A | LABELING BY BONDING A PHOSPHORAMIDITE OF A HYDROXYLAMINE | AMGEN INC. (US) | 1988-08-09 | — | — | US | disclosed |
| US-4739044-A | 3' END FUNCTIONALIZED POLYNUCLEOTIDE | AMGEN (US) | 1988-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026817-A1 | Polyamide-oligonucleotide derivatives, their preparation and use | POLRMT, POLR2H, POLN | FDPS 1478/4885LMNA 438/4885BLM 355/4885 |
| US-20030203359-A1 | Polyamide-oligonucleotide derivatives, their preparation and use | POLRMT, POLN, POLR2H | FDPS 1458/4885LMNA 259/4885BLM 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.